The once-celebrated company 23andMe has plummeted from its peak, with its market value now only 2% of its all-time high. Recently, it made headlines by announcing a 40% workforce reduction and the closure of its therapeutics division. Behind its market collapse, customer attrition, and internal turmoil lie the challenges of technological innovation and business model sustainability. As the world’s first direct-to-consumer genetic testing company, 23andMe once sought to break industry barriers, bringing complex and costly genetic sequencing to everyday people, earning widespread attention from investors. Another star company, uBiome, saw its two founders facing potential millennia-long prison sentences for fraud, marking a swift end to what was once a wealth-generating myth. What lessons can their failures teach future players? Is this truly the endgame for genetic testing?
Amid 23andMe's downfall, a new wave of companies focused on niche markets is quietly rising. The consumer genetic testing market is projected to grow from $1.9 billion in 2023 to $8.8 billion by 2030.
In this episode, Silicon Valley 101 host Jane Hongjun and N1 Life co-founder and CEO Dr. Janice delve into the history of the genetic testing industry’s rise and fall, discuss the transition between old and new players, and explore the future of this controversial yet opportunity-filled field.
In recent years, the once-renowned company 23andMe has fallen from grace, facing a sharp decline in valuation, loss of customers, and internal conflicts. Behind this downturn lie challenges in technological innovation and business models. As the world’s first direct-to-consumer genetic testing company, how did 23andMe break industry barriers and bring complex and costly genetic sequencing into everyday life? What lessons can its downfall offer to future players? In this episode, Silicon Valley 101 founder Jane Hongjun and N1 Life co-founder and CEO Dr. Xiaoyu Zhang dive into an in-depth discussion, exploring the rise and fall of the genetic testing industry and forecasting its future growth, expected to reach $8.8 billion by 2030.
"You Will Hear"
23andMe: Leveraging Internet Thinking to Drive Down the Cost of Genetic Testing
06:51 Ancestry: Curiosity about one's ancestors outweighs medical needs
08:30 Spreading the "Setup Fee": Bulk sequencing lowers unit costs
13:55 A Sexy Story, High Costs, Mediocre Products: 23andMe has never been profitable
17:09 A Double-Edged Sword: The rise and fall of 23andMe’s data strategy
28:26 The Next Generation of Genetic Testing Companies: Shifting from comprehensive testing to specialized niches
34:02 New Models for Genetic Testing: Subscription-based services, personalization, and value-added features
37:21 APOE and Alzheimer’s Disease: It’s still too early to diagnose diseases purely based on genetic targets
42:29 HER2 Genes: Current applications of genetic testing remain limited to specific areas
44:31 The Second Theranos: uBiome’s new brand of fraud
57:06 CRISPR’s Impact on Science: Comparable to that of generative AI
59:22 CAS Proteins and Guide RNA: Equipping the genetic editing scissors with "eyes"
01:01:46 The Challenges of Gene Therapy: Precisely delivering gene editors and drugs
"Host"
Dr. Janice graduated from Stanford University with a Ph.D. in Chemistry and has been deeply engaged in biopharmaceutical research. With nearly 15 years of academic and professional experience in the U.S., she is a trailblazing biotech entrepreneur who combines her scientific brilliance with a zest for life. Janice has published several high-impact academic papers and founded N1 Life in Silicon Valley. The company leverages cutting-edge molecular and computational technologies to innovate drug delivery systems and revolutionize the pharmaceutical industry. Known for her “United Nations” social circle, Janice connects with industry leaders and global nomads alike.
As the resident host of Aridrop从天而降, Janice shares her insights and experiences in science, entrepreneurship, and life exploration. She invites guests from various fields to discuss groundbreaking technologies and life philosophies.
"Guest"
Jane is the founder and CEO of *Silicon Valley 101*. A former magazine journalist and now a podcast creator, she was a U.S. correspondent for Finance Magazine and a lead writer for *Business Value* and *TMTPost*. She authored the column *Jane in Silicon Valley*, published in Finance Magazine and Tencent News. As a long-time observer of the tech industry, Jane is a concise and insightful speaker.
“Other Relevant Information”
Ancestry: One of the world’s largest genealogy research and DNA testing service providers. Founded in 1983, it offers billions of historical records. Its core services include online genealogy research, DNA testing, and family tree-building tools.
Illumina: A biotechnology company specializing in developing and selling gene sequencing instruments and reagents. Founded in 1998 and headquartered in California, Illumina’s products are primarily used by research institutions, hospitals, and pharmaceutical companies for genomic research and clinical applications. Its core business is Next-Generation Sequencing (NGS), a technology that enables high-throughput DNA and RNA sequencing, significantly accelerating genomic research and reducing costs. NGS is widely applied in cancer research, genetic disease screening, and microbiome analysis.
SelfDecode: A company offering genetic testing and personalized health insights. It integrates genetic data and AI algorithms to analyze DNA, generate health reports, and provide personalized recommendations for diet, nutrition, and lifestyle.
InsideTracker: A health analysis company that combines blood testing, DNA analysis, and lifestyle data to provide personalized health recommendations and optimization strategies. Its services include tracking biomarkers such as vitamin levels and inflammation indicators and providing dietary, exercise, and supplement suggestions based on the results.
10x Genomics: A biotechnology company founded in 2012 and headquartered in California. It focuses on technologies for single-cell genomics, transcriptomics, and spatial genomics. Its main products include single-cell analysis and spatial genome sequencing instruments and reagents, which help researchers analyze gene expression, cell properties, and spatial distributions at the single-cell level. These tools are widely used in cancer research, immunology, and neuroscience. 10x Genomics primarily serves research institutions and biopharmaceutical companies to advance disease research and develop new therapies.
Roche: A multinational healthcare company headquartered in Switzerland and founded in 1896. Roche focuses on pharmaceuticals and diagnostics, offering innovative drugs and diagnostic technologies for the treatment and detection of cancer, immune disorders, infectious diseases, and central nervous system disorders.
uBiome: Founded in 2012, uBiome was a microbiome genomics company that analyzed the human microbiome and provided health reports. Initially recognized for its direct-to-consumer testing products, it later shifted to relying on insurance reimbursement to scale operations. uBiome was accused of submitting testing fees for reimbursement without proper physician authorization and of inducing doctors to prescribe unnecessary tests to boost revenue. Additionally, the company faced allegations of exaggerating its technological capabilities and market demand, misleading investors. In 2019, the FBI raided its headquarters, leading to lawsuits and the company’s bankruptcy filing the same year.
LabCorp: Laboratory Corporation of America is a U.S.-based medical testing company headquartered in North Carolina. It provides a broad range of laboratory services, including blood testing, pathology, genomics, and toxicology, catering to hospitals, physicians, and patients.
Quest Diagnostics: One of the largest medical laboratory testing companies in the U.S., similar to LabCorp in its offerings. Its core services include routine medical testing, genetic testing, and health information services. Quest Diagnostics was also a key provider of testing during the COVID-19 pandemic.
APOE: Apolipoprotein E, a protein involved in lipid metabolism, plays a crucial role in regulating cholesterol and triglyceride levels in the blood.
HER2: Human Epidermal Growth Factor Receptor 2, a membrane receptor tyrosine kinase. HER2 is a significant target for various cancers, including breast cancer.
"Music"
Thank You by Dido
"Find Us Here"
Xiaoyuzhou | Ximalaya | Spotify | Apple Podcasts